Nagy Béla, Simon Zsuzsa, Bagoly Zsuzsa, Muszbek László, Kappelmayer János
Department of Clinical Biochemistry and Molecular Pathology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Thromb Haemost. 2009 Jul;102(1):83-9. doi: 10.1160/TH09-01-0054.
Platelet-bound coagulation factor XIII (FXIII) is targeted and concentrated at the site where platelet-rich thrombi are formed. Previous studies were in disagreement about the nature of FXIII binding to platelets. In this study, thrombin-receptor activating peptide (TRAP)-stimulated human whole blood and washed platelets were analysed by flow cytometry for the binding of FXIII using a monoclonal antibody against the A subunit of FXIII (FXIII-A). Here, we demonstrate that FXIII-A positivity significantly increased on activated platelets in whole blood compared to unstimulated sample, but not in washed platelets. GPIIb/IIIa receptor plays an essential role in FXIII binding, as fibrinogen receptor antagonist eptifibatide and fibrinogen binding inhibitor RGDS tetrapeptide significantly prevented the binding of FXIII. Furthermore, stimulated platelets from a patient with severe type I Glanzmann thrombasthenia showed insignificant FXIII-A positivity versus healthy controls. In addition, basal negligible amount of FXIII on washed platelets was only slightly increased when highly purified plasma FXIII (FXIII-A(2)B(2)) was added upon platelet activation by TRAP. Similarly, no remarkable FXIII-A positivity was observed when we used FXIII-A(2)B(2) with gammaA/gammaA fibrinogen. However, gammaA/gamma' fibrinogen significantly augmented FXIII binding on TRAP-stimulated platelets in the presence of non-activated FXIII-A(2)B(2). We conclude that FXIII-A(2)B(2) of plasma origin binds to thrombin-receptor activated platelets via GPIIb/IIIa receptor-bound fibrinogen with gamma'-chain and is not capable of direct platelet binding.
血小板结合凝血因子 XIII(FXIII)靶向并集中于富含血小板血栓形成的部位。先前的研究对于 FXIII 与血小板结合的性质存在分歧。在本研究中,使用抗 FXIII A 亚基(FXIII-A)的单克隆抗体,通过流式细胞术分析凝血酶受体激活肽(TRAP)刺激的人全血和洗涤血小板中 FXIII 的结合情况。在此,我们证明与未刺激样本相比,全血中活化血小板上的 FXIII-A 阳性显著增加,但在洗涤血小板中未增加。GPIIb/IIIa 受体在 FXIII 结合中起关键作用,因为纤维蛋白原受体拮抗剂依替巴肽和纤维蛋白原结合抑制剂 RGDS 四肽显著阻止了 FXIII 的结合。此外,与健康对照相比,严重 I 型 Glanzmann血栓形成症患者的刺激血小板显示出微不足道的 FXIII-A 阳性。另外,当通过 TRAP 激活血小板时加入高度纯化的血浆 FXIII(FXIII-A(2)B(2)),洗涤血小板上基础可忽略量的 FXIII 仅略有增加。同样,当我们将 FXIII-A(2)B(2)与γA/γA 纤维蛋白原一起使用时,未观察到明显的 FXIII-A 阳性。然而,在未活化的 FXIII-A(2)B(2)存在下,γA/γ'纤维蛋白原显著增强了 TRAP 刺激的血小板上的 FXIII 结合。我们得出结论,血浆来源的 FXIII-A(2)B(2)通过与γ'-链结合的 GPIIb/IIIa 受体结合的纤维蛋白原与凝血酶受体激活的血小板结合,并且不能直接与血小板结合。